

1 Competing Health Risks Associated with the COVID-19 Pandemic and Early Response: A
2 Scoping Review

3
4 Stefan Baral¹, Amrita Rao¹, Jean Olivier Twahirwa Rwema¹, Carrie Lyons¹, Muge Cevik², Anna
5 E. Kågesten³, Daouda Diouf⁴, Annette H. Sohn⁵, Nancy Phaswana-Mafuya⁶, Adeeba
6 Kamarulzaman⁷, Gregorio Millett⁸, Julia L. Marcus⁹, Sharmistha Mishra¹⁰

7
8 **Author Affiliations**

- 9 1) Department of Epidemiology, Johns Hopkins School of Public Health, Baltimore, MD
10 2) Division of Infection and Global Health Research, School of Medicine, University of St.
11 Andrews, Scotland
12 3) Department of Global Public Health, Karolinska Institutet, Sweden
13 4) Enda Santé, Dakar, Senegal
14 5) TREAT Asia, amfAR, the Foundation for AIDS Research, Bangkok, Thailand
15 6) Department of Environmental Health, Faculty of Health Sciences, University of
16 Johannesburg
17 7) University of Malaya, Kuala Lumpur, Malaysia
18 8) Public Policy Office, amfAR, Washington DC
19 9) Department of Population Medicine, Harvard Medical School and Harvard Pilgrim
20 Health Care Institute, Boston, MA
21 10) Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Toronto,
22 Canada

23
24 **Disclosures**

25 Annette Sohn and Gregorio Millett report funding from ViiV Healthcare. Julia Marcus has
26 consulted in the past for Kaiser Permanente Northern California on a research grant from Gilead
27 Sciences. All other authors report no competing interests.

28
29 **Funding**

30 Amrita Rao is supported in part by the National Institute of Mental Health [F31MH124458].
31 Julia Marcus is supported in part by the National Institute of Allergy and Infectious Diseases
32 [K01AI122853]. Sharmistha Mishra is supported by a Tier 2 Canada Research Chair in
33 Mathematical Modeling.

34
35 **License**

36 The Corresponding Author grants on behalf of all authors, a worldwide license to publishers and
37 licensees for this work.

38
39 **Author Contributions**

40 The article was conceptualized by SB, AR, JOT, and CL. SB led manuscript development. AR,
41 JOTR, CL led the literature reviews with AR synthesizing literature for HIV, JOT for
42 malnutrition, CL for malaria, MC for tuberculosis, and AEK for selected sexual and reproductive
43 health outcomes. AHS led writing of global research agenda, GM on policy, and SM on
44 mathematical modeling. AEK, DD, RPM, and JM drafted other sections of the manuscript. All
45 authors reviewed and agreed upon the final version of the manuscript. This assessment
46 represents the views of the authors and not official positions of their employers.

47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92

Words: 4738

Abstract

Background

COVID-19 has rapidly emerged as a global public health threat with infections recorded in nearly every country. Responses to COVID-19 have varied in intensity and breadth, but generally have included domestic and international travel limitations, closure of non-essential businesses, and repurposing of health services. While these interventions have focused on testing, treatment, and mitigation of COVID-19, there have been reports of interruptions to diagnostic, prevention, and treatment services for other public health threats.

Objectives

We conducted a scoping review to characterize the early impact of COVID-19 on HIV, tuberculosis, malaria, sexual and reproductive health, and malnutrition.

Methods

A scoping literature review was completed using searches of PubMed and preprint servers (medRxiv/bioRxiv) from January 1st to October 31st, 2020, using Medical Subject Headings (MeSH) terms related to SARS-CoV-2 or COVID-19 and HIV, tuberculosis, malaria, sexual and reproductive health, and malnutrition. Empiric studies reporting original data collection or mathematical models were included, and available data synthesized by region. Studies were excluded if they were not written in English.

Results

A total of 1604 published papers and 205 preprints met inclusion criteria, including 8.2% (132/1604) of published studies and 10.2% (21/205) of preprints: 7.3% (68/931) on HIV, 7.1% (24/339) on tuberculosis, 11.6% (26/224) on malaria, 7.8% (13/166) on sexual and reproductive health, and 9.8% (13/132) on malnutrition. Thematic results were similar across competing health risks, with substantial indirect effects of the COVID-19 pandemic and response on diagnostic, prevention, and treatment services for HIV, tuberculosis, malaria, sexual and reproductive health, and malnutrition.

Discussion

COVID-19 emerged in the context of existing public health threats that result in millions of deaths every year. Thus, effectively responding to COVID-19 while minimizing the negative impacts of COVID-19 necessitates innovation and integration of existing programs that are often siloed across health systems. Inequities have been a consistent driver of existing health threats; COVID-19 has worsened disparities, reinforcing the need for programs that address structural risks. The data reviewed here suggest that effective strengthening of health systems should include investment and planning focused on ensuring the continuity of care for both rapidly emergent and existing public health threats.

93 **Introduction**

94
95 The coronavirus disease 2019 (COVID-19) pandemic is among the most significant public health

96 emergencies of international concern over the last hundred years causing substantial morbidity

97 and mortality worldwide [1]. Public health responses to COVID-19 have varied in intensity,

98 breadth, and duration, but in many countries have included domestic and international travel

99 restrictions, stay-at-home orders and curfews, closure of non-essential businesses and schools,

100 and repurposing of health services [2]. Although the goals of these interventions are to mitigate

101 transmission of SARS-CoV-2 and ensure sufficient capacity for testing and treatment, such

102 measures also have broader social, economic, and health impacts, including disruptions to

103 routine public health programs and other clinical services [3-7]. Even when prevention or

104 treatment services have remained uninterrupted, some people have been unwilling to seek care at

105 healthcare facilities because of concerns about nosocomial SARS-CoV-2 acquisition risk or the

106 misconception that services are only available for patients with COVID-19[8].

107 Taken together, COVID-19 may have profound indirect and longer-term effects on broader

108 health outcomes, including morbidity and mortality associated with other infectious and

109 noncommunicable diseases. Moreover, there may be increased risks of indirect health effects of

110 the COVID-19 pandemic in low- and middle-income countries because of suboptimal healthcare

111 resources and infrastructure. Within all countries, existing socioeconomic inequities, driven in

112 part by structural racism, are likely to shape who is most affected, both directly and indirectly, by

113 COVID-19. Marginalized groups that already experienced inadequate access to prevention,

114 diagnostic, and treatment services, as well as a higher prevalence of other health conditions, may

115 be most profoundly impacted by further interruptions to prevention, diagnostic, and treatment

116 services during the pandemic response.[9] Understanding the indirect effects of COVID-19 on

117 health services, overall health outcomes, and equity is critical for planning and adapting public
118 health responses to emerging infections, which need to maximize control of outbreaks while
119 minimizing setbacks in other areas of health.

120 The objective of this review was to characterize the impact of early mitigation measures for the
121 COVID-19 pandemic on health conditions that cause significant morbidity and mortality,
122 including services and outcomes related to HIV infection, tuberculosis (TB), malaria, sexual and
123 reproductive health (SRH), and malnutrition. To that end, we used a scoping rather than
124 systematic review to summarize research findings and reporting from a range of different data
125 sources and study types [10]. The results of the scoping review are synthesized, including
126 implications for global health investments and policies that can mitigate the indirect effects of
127 COVID-19 and future public health emergencies of international concern.

128

129 **Methods**

130 We conducted a scoping review of published papers and preprints through October 31, 2020.

131 Search strategies (**Appendix**) were developed using MeSH and key terms to focus on COVID-19
132 and its impact on one of the pre-specified key competing health risks: HIV, TB, malaria, SRH
133 (contraceptives, abortion, pregnancy-related and newborn care), and malnutrition. Abstracts and
134 full-text articles were reviewed using Covidence[11], an online systematic review management
135 tool, and EndNote (version X8) [12].

136 For published papers, searches were implemented in PubMed. For preprints, we conducted a
137 search of the COVID-19 Living Evidence Database, which includes published papers and
138 preprints from both medRxiv and bioRxiv and is updated daily

139 (https://zika.ispm.unibe.ch/assets/data/pub/search_beta/).

140 Articles were eligible for inclusion if the primary focus was the impact of COVID-19 on one of
141 the five listed public health threats, and if they included empiric data or mathematical models on
142 health or service outcomes. We excluded articles not written in English. Commentaries were
143 screened for key themes to support interpretation of the measured and modeled data. Articles
144 were included if they were published or posted between November 2019 and October 2020 with
145 the most recent search implemented on October 31, 2020.

146 Titles and abstracts were reviewed by a single reviewer and selected for inclusion in this review
147 based on the above criteria. The reviewers of each of the sections were as follows: HIV (AR),
148 TB (CL), malaria (CL), SRH (JOTR), and malnutrition (JOTR). **Table 1** depicts the number of
149 articles pulled, formally included based on the inclusion criteria, designated as commentaries,
150 and excluded. Included articles were reviewed and an initial scan was completed for available
151 empiric data or mathematical models and themes in terms of epidemiology of the burden or
152 associated mortality of the condition and changes to service delivery. Some key indicators
153 included changes in new infections and coverage of prevention and treatment services.
154 Following this initial scan, calibration meetings were held in order to refine data charting
155 processes, and final charting and synthesis were done independently.

156

157 **Results**

158 **Outcomes of the Scoping Review**

159 The systematic search identified a total of 1604 published papers and 205 preprints. For articles
160 related to the impact of COVID-19 on the HIV pandemic, 7.3% (68/931) were deemed relevant
161 and included in this review, along with 7.1% (24/339) for TB, 11.6% (26/224) for malaria, 7.8%

162 (13/166) for SRH, and 9.8% (13/132) for malnutrition. The number of selected papers that were
163 screened and eligible are reported in **Table 1**.

164 **Summary of Charted Results**

165 It was found that COVID-19 has been associated with reduced access to services, decreased
166 diagnosis, and poorer health outcomes for HIV, TB, malaria, and SRH, and increases in
167 malnutrition.

168 **COVID-19 Impact on HIV Services**

169 Three main themes emerged from a review of the literature related to the potential impact of
170 COVID-19 on HIV. The majority of papers included in this review described a destabilization of
171 HIV service delivery and the negative impact of COVID-19 mitigation efforts on HIV testing,
172 access to care, and viral suppression.[13, 14] Across geographic contexts, including in Australia,
173 Indonesia, Italy, Kenya, and Uganda, fewer people living with HIV reported being able to attend
174 clinic visits and access antiretroviral therapy (ART), resulting in a decline in the number of
175 people estimated to be virally suppressed [15-19]. For example, in a global survey of men who
176 have sex with men (MSM), close to 20% (218/1105) reported being unable to access their HIV
177 provider during the pandemic and half reported being unable to refill their HIV prescription
178 remotely (820/1254).[18] In terms of HIV prevention, there was a decline in the number of
179 people being tested and diagnosed [15, 20-22] and the amount of pre-exposure prophylaxis
180 (PrEP) [23, 24] and post-exposure prophylaxis dispensed[18, 25, 26], although these declines
181 may have been attributable in part to reductions in sexual activity [23, 24]. For example, one
182 study of 847 gay and bisexual men in Australia found that about 42% discontinued PrEP use
183 during the COVID-19 pandemic and that those discontinuing were less likely to report casual
184 sexual partners [23]. COVID-19 responses have resulted in interruptions to the supply chains for

185 the distribution of both ART and PrEP, and stock-outs of medications, as one study from
186 Indonesia described.[16]

187 Disparities were also identified in who was affected by interruptions to HIV prevention and
188 treatment services. Specifically, existing socioeconomic inequities, including reduced access to
189 health insurance and unstable housing, were associated with HIV service interruptions.[14, 27]

190 In addition, key populations—including MSM, female sex workers, people who use drugs, and
191 transgender populations—that depend on services from community-based organizations because
192 of stigma within the health sector may have been particularly vulnerable to disruptions in
193 outreach services caused by shelter-in-place mandates [28-30].

194 In some settings, there were reported adaptations in the implementation of HIV service delivery
195 to mitigate interruptions, including adoption of telemedicine [19, 31-36]; home-based HIV
196 testing and self-testing[37-39]; home or mobile delivery of ART[34, 35, 40]; use of curbside
197 pickup (i.e. pickup of supplies without stepping out of a vehicle) for condoms, lubricants, and
198 medications[41]; and designation of surrogates such as peers to motivate and support ongoing
199 treatment.[19] Adaptation of clinical services benefited from training of providers and
200 approaches that promoted trust and took into consideration patients' needs and preferences.[32]

201 Access to non-medical support, including cash transfers, reimbursement for the costs associated
202 with accessing care,[19] and housing and food supplementation support were key to promoting
203 ongoing engagement in care.[29, 39] However, medical support and telemedicine strategies
204 alone were unlikely to fully mitigate the poorer HIV outcomes observed; one study from a
205 safety-net HIV clinic in San Francisco found that the odds of viral non-suppression were 31%
206 higher after a shelter-in place mandate compared to before the mandate, even with telemedicine

207 services.[14] Notably, most studies describing adaptations were in higher-income settings,
208 though this may be reflective of a publication bias.

209 **COVID-19 Impact on TB Care Cascade**

210 Over the past several years, TB incidence and mortality have been steadily declining because of
211 improvements in diagnosis, treatment, and prevention. The data available to date suggest that
212 COVID-19 has resulted in disruptions that may challenge the WHO goal to end the TB pandemic
213 by 2030.

214 Reductions in timely diagnosis and treatment of new TB cases have resulted from COVID-19-
215 related disruptions to access to healthcare services and availability of diagnostic capacity.

216 Overwhelmed healthcare systems have often de-prioritized TB testing in laboratories and
217 diverted these resources to COVID-19 testing [42]. In South Africa and Nigeria, for instance,
218 GeneXpert machines and kits were prioritized for COVID-19 testing, leading to a drop of more
219 than 50% in the median number of daily GeneXpert TB tests[43, 44]. Social distancing
220 measures implemented in many countries disrupted patients' access to care, which impeded
221 diagnosis, initiation of appropriate treatment, and follow-up. In Bangladesh, Kenya, Nigeria and
222 Pakistan, the ability of residents in lower-income communities—which have a higher risk of
223 TB—to seek healthcare for TB services has been reduced during COVID-19-related
224 restrictions[45]. Missed diagnoses increase opportunities for transmission, while worsened
225 treatment outcomes increase the risk of TB-related morbidity and mortality.

226 There have also been documented interruptions to services for people diagnosed with TB [46,
227 47]. For instance, in early 2020, there had been a substantial reduction in TB notifications in
228 China, India, Japan, Nigeria, the Philippines, Sierra Leone, South Korea, and the United States
229 compared with the same period in previous years [48-57]. Specifically, there was a decline of

230 more than 50% in TB notifications in China in 2020 compared to 2015–2019.[58] Furthermore,
231 in Nigeria and South Korea, there was a one-third decrease in the number of active TB
232 notifications in 2020 compared with prior years. As restrictive measures were lifted and COVID-
233 19 rates declined, most of these settings reported an increase in TB notification rates [48-57]. In
234 addition, reduced access to healthcare services and re-deployment of the TB workforce for the
235 management of COVID-19 [59, 60] have created conditions for low adherence to treatment,
236 which might also contribute to ongoing transmission and the emergence and spread of drug-
237 resistant TB. During COVID-19-related restrictions in China, patient treatment completion and
238 screening for drug-resistant TB among new and high-risk TB patients declined by approximately
239 20% [48].

240 At a broader level, COVID-19 prevention and mitigation measures have increased poverty and
241 undernutrition, which are major risk factors for the acquisition and active conversion of TB. In
242 India, an estimated 140 million people have lost their jobs during COVID-19 [61]. In Brazil, the
243 regions hardest hit by COVID-19 largely overlap with the regions where higher TB rates are
244 observed [62]. With increased poverty and undernutrition, TB cases may surge among these
245 disadvantaged communities. Furthermore, as regular services continue to be disrupted, routine
246 TB immunization programs have been affected, such as in Pakistan, where an over 40% decline
247 in BCG vaccinations has been reported [63].

248 Multiple modelling studies have estimated that COVID-19-related disruptions and fragmentation
249 of TB services could result in an increase in TB incidence and mortality[64, 65]. The Stop TB
250 Partnership reported that without countermeasures to maintain TB services, a 3-month period of
251 COVID-19 restrictions followed by a 10-month recovery period could lead to an additional 6.3
252 million cases of TB by 2025 and an additional 1.4 million TB-related deaths in low- and middle-

253 income countries[66]. Another modelling study estimated that over the next 5 years, these deaths
254 could increase by up to 20%[67]. This emphasizes that the adverse effects of short-term
255 disruptions will need to be addressed through “catch-up” TB case detection and treatment
256 programs[68]. Critical efforts to mitigate impacts on TB control could include integration of TB
257 and COVID-19 services for infection control, contact tracing, community-based care,
258 surveillance, and monitoring. Innovative ways to deliver medicines and collect specimens for
259 follow-up TB testing at home, and combine screening for TB and COVID-19, have already been
260 demonstrated in South Africa [40, 69]. The socioeconomic inequities driving both TB and
261 COVID-19 highlight the need for all countries to invest in universal health coverage and ensure
262 equitable access to services.

263 **COVID-19 Impact on Malaria Services**

264 Studies have collectively demonstrated challenges in maintaining malaria prevention and control
265 efforts in the context of COVID-19. In a study of 106 countries, 73% of malaria programs
266 reported disruptions to service delivery, of which 19% reported high or very high levels of
267 disruptions, potentially leading to increased morbidity and mortality.[70, 71] A resurgence of
268 malaria due to COVID-19 may occur overall, and especially among vulnerable young children
269 and pregnant women.[72-74] Of particular concern is the disruption of prevention efforts,
270 including routine distribution of long-lasting insecticide-treated nets, seasonal malaria
271 chemoprevention, and indoor residual spraying of insecticide.[72, 75] A modeling study
272 suggested that the greatest impact on malaria burden could result from interruption of planned
273 bed net campaigns, predicting 36% more deaths over 5 years in high-burden settings than would
274 have occurred without COVID-19-related disruptions.[67] Another mathematical model
275 suggested that COVID-19-related disruptions to malaria chemoprevention efforts and

276 distribution of insecticide-treated nets in sub-Saharan Africa may have contributed to a doubling
277 of malaria-related mortality in 2020.[76]

278 Malaria diagnoses during the COVID-19 outbreak have decreased, with a reduction in the
279 notification rate as high as 62% in some settings.[77, 78] This reduction in diagnoses may be due
280 to several factors, including reductions in health-seeking behavior related to malaria, as
281 individuals may be reluctant to visit health facilities due to COVID-19.[72, 77] Conversely,
282 healthcare providers previously focused on delivering malaria care may have been reassigned to
283 work on COVID-19, therefore limiting available malaria diagnostic services. COVID-19 and
284 malaria have overlapping symptoms, including fever, difficulty breathing, headaches, and body
285 pain, and there may be misdiagnosis of these infections in the context of limited laboratory
286 testing.[79, 80] Furthermore, delays in reporting of malaria testing and confirmed cases have
287 been observed, possibly due to disruptions in surveillance reporting structures.[77] Overall,
288 undetected malaria infections as a result of the focus on COVID-19 testing threaten malaria
289 control efforts.[81]

290 Chloroquine (CQ) and its derivative, hydroxychloroquine (HCQ), are established prophylactic
291 and clinical treatments for malaria and widely used in endemic areas. Early in the COVID-19
292 pandemic, these antimalarials were considered for potential treatment of COVID-19, and the
293 U.S. FDA issued a temporary emergency use authorization for the use of HCQ for treatment of
294 COVID-19, which was then rescinded in June 2020.[82] Across settings, there was a
295 documented increase in prescriptions of antimalarials, including an 80-fold increase in HCQ
296 prescriptions in the U.S.[82] [83] Indiscriminate and widespread prophylactic and therapeutic
297 use of CQ and HCQ for COVID-19 may complicate malaria prevention and control through
298 several mechanisms. Alongside the increase in demand, shortages in the immediate supply may

299 reduce their availability for use in malaria prevention and control, especially in low- and middle-
300 income settings, which rely on international supply chains.[84, 85] Importantly, resistance to CQ
301 and HCQ has previously emerged, and further indiscriminate use due to COVID-19 may drive
302 Plasmodium resistance in malaria-endemic areas and threaten malaria control. [74, 81, 83, 86]

303 **COVID-19 Impact on Sexual and Reproductive Health Services**

304 In terms of the impact on SRH, we focused on early disruptions in selected essential services,
305 including contraceptives, abortion, and pregnancy-related and newborn care [87]. Other SRH
306 services and outcomes (e.g., screening, prevention, and care related to sexually transmitted
307 infections, sexual violence, and reproductive cancers) were beyond the scope of our review.
308 Early during the COVID-19 outbreak, Robertson et al.[88] estimated that a 10-52% drop in
309 service coverage would result in 12,000-57,000 additional maternal deaths over a 6-month period
310 in low- and middle-income countries. Similarly, Riley et al predicted that a 10% decline in SRH
311 services would add 15.4 million unintended pregnancies, 3.3 million unsafe abortions, and
312 28,000 additional maternal deaths on a yearly basis [89]. Studies conducted during the initial
313 phases of the pandemic outbreak and response further highlight SRH-related service disruptions,
314 including 60 million fewer contraceptive users. These numbers are highest in Sub-Saharan
315 Africa, Latin America, and the Caribbean, where the prevalence of provider-administered
316 methods requiring face-to-face contact (such as injectable contraception) is the highest [90, 91].
317 Social distancing measures have resulted in interruptions to commodity production, supply chain
318 delays, and clinic closures, resulting in commodity shortages.[92] In India, Marie Stopes
319 International reported serving 1.3 million fewer women with contraceptive and abortion services
320 than expected.[93] At the time the current search was conducted, research studies had
321 documented mixed results in terms of the impact of COVID-19 on SRH service delivery

322 outcomes [94-96]. Decreases in access to and use of contraceptives, antenatal care, safe abortion,
323 and institutional delivery have been documented across different health systems and income
324 contexts, including Kenya,[97, 98] Ethiopia,[99] Turkey,[100] Italy,[101], UK,[102] and the
325 US.[103-105] Notably, a recent large-scale prospective observational study in Nepal found a
326 52% decrease in institutional births coupled with increased neonatal mortality rates and poor
327 intrapartum care during COVID-19-related restrictions [106].

328 Frontline maternal health workers have described changed care practices globally, such as
329 relocation of human resources to the COVID-19 response, reduced face-to-face consultations,
330 visitor bans (including for partners), and shorter post-delivery stays for mothers and infants [107-
331 113]. Several adaptations have been introduced to mitigate the effects of these health systems
332 challenges [114], including the Kenyan "Wheels for life initiative" to provide free transportation
333 services to pregnant women during curfew hours,[97] "click and collect" access to
334 contraceptives,[115] and increased transition to telemedicine [111, 114-117]. In particular,
335 newly imposed abortion restrictions in a number of European countries[118] and the US[103,
336 104, 119] during the initial COVID-19 outbreak have created an increased demand for medical
337 abortion via telemedicine in several countries [118, 120-123]. This has been authorized in the
338 UK in order to ensure equity and continuity of abortion care during COVID-19 [118]. However,
339 technology requirements and legal restrictions on abortions mean that many women who need
340 these adapted services will not be able to access them [120, 123]. These programs and
341 workarounds highlight a demand for self-care services that will likely persist or grow in the
342 future [124].

343 **COVID-19 Impact on Nutrition Services**

344 The immediate effect of COVID-19 on nutrition has been an increase in the number of
345 individuals facing food insecurity in low-, middle-, and high-income countries[125, 126]. Food
346 insecurity appears to be related to disruption of food supply chains due to limited movements of
347 people and goods between countries, which in turn caused a disruption of food markets,
348 increased food waste, and inflation of food prices.[127-129] This disruption of markets was
349 exacerbated by the economic fallout associated with COVID-19, resulting in millions of people
350 losing their sources of income, particularly in low- and middle-income countries, where the
351 majority of individuals work in the informal sector. Though food insecurity has affected
352 individuals of all demographics, children and women of low socioeconomic status have been
353 particularly affected by service interruptions due to COVID-19, and the effects may be long-
354 lasting among these populations.

355 School closures have resulted in loss of access to healthy foods for millions of school-aged
356 children and adolescents who relied on schools to access healthy meals[130-132]. In addition,
357 among children less than five years of age, malnutrition has been projected to increase, resulting
358 in substantial morbidity and mortality, especially among children [133]. For instance, a
359 modelling study focusing on 118 low- and middle-income countries (LMIC) estimated that the
360 disruptions in health services and increase food insecurity due to COVID-19 could result in a
361 14% increase in the prevalence of malnutrition, translating to 6.7 million more children under
362 five experiencing severe malnutrition. The same study estimated that COVID-19 would be
363 associated with more than 120,000 additional deaths among children under five because of
364 increased malnutrition and other unmet child health needs. Maternal mortality is also expected
365 to increase as a result of increased food insecurity and reduced access to maternal health
366 programs [133, 134]. Specifically, a separate modelling study estimated an additional 12,200 to

367 56,700 maternal deaths could occur as a result of disruption in maternal health and nutrition
368 programs in LMIC [88].

369 Given the substantial negative effects on nutrition and the associated morbidity and mortality,
370 several papers have lamented the lack of explicit nutrition programs in the COVID-19 response
371 and called for integration of nutrition programs within COVID-19 mitigation strategies. Specific
372 strategies to mitigate increased malnutrition could include population-level interventions to
373 support the communities most vulnerable to malnutrition[135]. In Nepal, for example, specific
374 interventions to offset risks associated with restrictive COVID-19 interventions included
375 continuation of vitamin A supplementation and provision of deworming tablets to children,
376 programs supporting breastfeeding and other complementary foods, distribution of fortified
377 foods to pregnant women, and ensuring the continuity of other existing maternal and child
378 programs[134].

379 In addition to food insecurity, there has been an increase in unhealthy eating habits since the start
380 of COVID-19. A cross-sectional study among over 1000 adult participants in Poland found that
381 43% of participants reported eating more frequently and 50% reporting more snacking.

382 Furthermore, 30% of participants in the study reported weight gain since the initiation of
383 COVID-19-related restrictions [136], while 15% of participants reported consuming more
384 alcohol and 45% of smokers reported increased smoking frequency.

385 **Discussion**

386 Across high-, middle-, and lower-income countries, COVID-19 has been associated with reduced
387 access to services, decreased diagnosis, and poorer health outcomes for HIV, TB, malaria, and
388 SRH, and increases in malnutrition. The most affected populations appear to be communities
389 already on the margins, including those with lower income, racial and ethnic minorities, and

390 women, resulting in the amplification of existing health inequities. In 2015, all United Nations
391 Member States adopted the 2030 Agenda for Sustainable Development with a focus on 17
392 Sustainable Development Goals. To support health and wellbeing for all, the Sustainable
393 Development Goals laid out ambitious plans for zero new HIV, malaria, and TB infections by
394 2030, and ambitious goals to address malnutrition and reproductive health. Increases in
395 communicable diseases and malnutrition, worsened reproductive health outcomes, and widening
396 inequities could collectively result in a reversal of global health gains in key indicators[137].

397
398 The indirect effects of the COVID-19 pandemic may force a reexamination of global health
399 investments and policies. Specifically, it has been estimated that as much as 90% of countries
400 have experienced declines in per capita income due to the COVID-19 pandemic and responses
401 [138]. These decreases have prompted questions regarding the viability of the Sustainable
402 Development Goals and whether they should reflect more achievable targets in the wake of
403 programmatic disruptions due to COVID-19 [139]. In addition, as service disruptions and
404 COVID-19-related restrictions are expected to disproportionately affect already-marginalized
405 groups—such as adolescents, sexual and gender minority communities, people living with HIV,
406 refugees and migrants, and people facing gender-based violence[89, 98, 140-142]—human-rights
407 affirming, intersectional approaches for monitoring and addressing the indirect effects on
408 programs are critical [18] [140]. Specific funding support to non-governmental organizations
409 with strong connections to these communities may be able to overcome disruptions in health
410 services during public health emergencies. Moreover, efforts to decriminalize marginalized
411 populations should be prioritized to promote legal and economic opportunities, as well as access
412 to health care. Finally, there have been calls for more resilient supply chains for medicine and

413 food in low- and middle-income countries. This requires supporting local market chains and
414 removing intellectual property barriers to and within those countries to avoid reliance on
415 international food and medicine supply chains and strengthen their production and delivery of
416 biofortified foods and pharmaceutical interventions. [128] The importance of local production of
417 pharmaceutical products including vaccines has been highlighted throughout COVID-19 given
418 the extreme inequities that have defined COVID-19 vaccine distribution, availability, and
419 ultimately, coverage.

420 Despite differences of opinion in specific policy actions, there are a few areas where a broad
421 consensus is emerging. Multilateral initiatives and commitments are more important than ever,
422 and donors must redouble their efforts to invest in global health efforts rather than retrench to
423 keep from losing decades of gains. COVID-19 has stressed the capacity of health systems
424 because of vertical and siloed health infrastructure designed to respond to specific diseases.
425 Integrated health systems can not only address a multiplicity of health issues, but also can
426 support integrated surveillance, data systems, supply chain management, and delivery[143]. To
427 inform these policy initiatives, there is a need for disease-specific approaches to shift towards
428 studying communities of individuals and health systems.

429 The benefits of scientific discovery are not linear with respect to disease. For instance, scientific
430 advances in HIV have benefited cancer and hepatitis research, and have served as a basis for
431 COVID-19 vaccines.[144, 145] Similarly, these health conditions themselves are interrelated.
432 For instance, TB is the leading cause of death for people living with HIV in sub-Saharan
433 Africa.[146] However, disease-specific research has often failed to study and respond to the
434 complexities of this reality. Before COVID-19, for example, it would have been unusual to
435 conduct research on the impact of a respiratory virus infection on domestic violence, depression,

436 and job security among women living with HIV who were diabetic. However, given anecdotal
437 and media reports of these relationships, research should evolve accordingly to better inform the
438 lived realities of the public. Cross-disciplinary research initiatives can characterize the direct and
439 indirect impacts of COVID-19, including implementation research on syndemic-related health
440 outcomes, effects of legal policies and increased policing (e.g., protections for marginalized
441 populations), structural racism, and issues of food security and employment.[147-150] In
442 addition, studies on optimizing resource allocation and supply chain management for
443 therapeutics and vaccines are critical to avoid worsening of inequities during scale-up.[151] To
444 respond to these needs, the WHO convened a Global Research Forum early in February 2020 to
445 accelerate research on the immediate priorities of COVID-19 mitigation and treatment, with
446 secondary aims to build up global research platforms and drive equitable access to diagnostics
447 and therapeutics.[117] Moreover, there was to be intentional assessment of how public health
448 strategies may impact a multitude of factors across physical and mental health, as well as social
449 infrastructure, economies, and politics.[152-154]

450 Mathematical models have played a significant role in COVID-19-related decision-making. As
451 in previous outbreaks and pandemics, transmission dynamics and statistical modelling provided
452 rapid estimates drawing on rapidly evolving information[155] [156]. Similar to the policy and
453 research initiatives to date, infectious disease modelling has remained largely “vertical”, or
454 siloed by health threats, thus resembling and informing decision-making for vertical health
455 services. As models are expected to continue to drive decision making, the next generation of
456 pandemic preparedness models could integrate case projection for an emerging infectious
457 disease, and disease-specific health care and public health needs, with adaptive strategies for a
458 resilient health care system. In projecting how many acute care hospital beds might be needed to

459 care for patients with severe COVID-19, integration of other conditions could inform strategies
460 to manage the surges while also minimizing disruptions to other health care services. For
461 example, if estimates of the reduction in contact rates required to decrease SARS-CoV-2 spread
462 were integrated, a priori, decision-makers could better understand differential COVID-19
463 mitigation strategies alongside systems-level modelling to inform decision-making across health
464 services[157]. Separate from variability in underlying mortality, health system infrastructure
465 varies significantly across regions, including health and human services per population or in-
466 hospital and intensive care beds per capita. Further integration of localized health infrastructure
467 parameters with COVID-19 transmission models would also support localized decision making
468 for optimal interventions [158-160].

469
470 There are several limitations of this scoping review. Given the breadth of information reviewed,
471 including over 1800 peer-reviewed and preprint articles, we did not conduct a formal population-
472 intervention-control-outcome systematic review. In addition, the search strategy was only
473 implemented in PubMed, medrxiv, and biorxiv, which means we may have missed other articles
474 that were only indexed in other databases. Moreover, there were several areas not covered in this
475 review, including vaccine-preventable diseases[161], non-communicable diseases[162, 163],
476 specific health effects among migrant communities[164], violence[165], and mental health[166].
477 The timing of this review includes a focus on 2020 representing the earlier phase of the
478 pandemic and early mitigation efforts though a non-systematic assessment in November, 2021
479 suggested that the trends reported were sustained. Preliminary data suggest effects across all
480 these areas, including reports of increased domestic violence, decreases in childhood
481 vaccinations, and increases in mortality and morbidity because of acute mental health stressors

482 and substance use. In addition, publication bias may have affected the estimates reported here.
483 Because we did not complete a quantitative meta-analysis, we were unable to assess the
484 magnitude of publication bias. Finally, there may be limited generalizability of the indirect
485 effects of COVID-19 across regions given significant variability in the underlying causes of
486 morbidity and mortality and varying health systems and health infrastructure.

487 **Conclusions**

488 The COVID-19 pandemic has exposed disparate risks and inequities by income, race and
489 ethnicity, gender, and immigration status. The results of this scoping review demonstrate ways
490 that the COVID-19 pandemic and response have impacted other diseases and essential services,
491 risking decades of progress in outcomes associated with HIV, TB, malaria, sexual and
492 reproductive health, and malnutrition. Given vaccine inequity, the places most affected by these
493 conditions were also the least able to support the vaccination of their population—likely causing
494 even greater morbidity and mortality. Many settings have adapted by developing programs to
495 mitigate the indirect effects of COVID-19, but optimizing population-level health in the context
496 of public health emergencies of international concern necessitates broader innovation in research,
497 mathematical modeling, policy, and programs. Moreover, a cross-disciplinary research agenda
498 for pandemic preparedness and response modelling offers an opportunity to examine optimal
499 decision making for health care and public health systems by integrating counterfactuals (‘what
500 if’ experiments) for one disease with those for other health conditions. COVID-19 responses
501 should also include a rights-based approach that helps ensure equitable access to prevention,
502 diagnostic, and treatment services for both COVID-19 and competing health risks. The redesign
503 and strengthening of health systems must include the strengthening of public health systems,
504 with adequate funding and planning to ensure continuity of contextually relevant health and

505 social welfare programs that specifically address the needs of communities most socially and
506 economically marginalized.

507

508

509

510

511

512

513

514

515

516

517 **Table 1.** Number of papers pulled, included, marked as relevant commentaries, and excluded by
518 competing health risk as part of the scoping review

PUBLISHED LITERATURE (PubMed)					
	HIV	Malaria	Malnutrition	SRH	TB
Pulled	827	189	125	162	301
Included	60	23	13	13	20
Commentaries	43	24	27	60	58
Excluded	724	165	82	89	223

519

PREPRINTS (COVID-19 Living Evidence database)					
	HIV	Malaria	Malnutrition	SRH	TB
Pulled	104	35	7	21	38
Included	8	3	0	6	4
Commentaries	0	0	0	0	1
Excluded	96	32	7	15	33

520 SRH=Sexual and Reproductive Health; TB=Tuberculosis

521

522

523

524

525

526

527

528

529

530

531

532

533

534

535 **References**

536

- 537 1. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in
538 real time. *The Lancet Infectious Diseases*. 2020;20(5):533-4. doi: 10.1016/S1473-
539 3099(20)30120-1.
- 540 2. Holland CE, Kouanda S, Lougue M, Pitche VP, Schwartz S, Anato S, et al. Using
541 Population-Size Estimation and Cross-sectional Survey Methods to Evaluate HIV Service
542 Coverage Among Key Populations in Burkina Faso and Togo. *Public Health Rep*.
543 2016;131(6):773-82. doi: 10.1177/0033354916677237. PubMed PMID: 28123223; PubMed
544 Central PMCID: PMCPMC5230836.
- 545 3. Kazi DS, Wadhwa RK, Shen C, Ho KKL, Patell R, Selim MH, et al. Decline in Emergent
546 and Urgent Care during the COVID-19 Pandemic. medRxiv. 2020:2020.05.14.20096602. doi:
547 10.1101/2020.05.14.20096602.
- 548 4. Hartnett KP, Kite-Powell A, DeVies J, Coletta MA, Boehmer TK, Adjemian J, et al.
549 Impact of the COVID-19 Pandemic on Emergency Department Visits - United States, January 1,
550 2019-May 30, 2020. *MMWR Morb Mortal Wkly Rep*. 2020;69(23):699-704. Epub 2020/06/12.
551 doi: 10.15585/mmwr.mm6923e1. PubMed PMID: 32525856; PubMed Central PMCID:
552 PMCPMC7315789 Journal Editors form for disclosure of potential conflicts of interest. No
553 potential conflicts of interest were disclosed.
- 554 5. Hungerford D, Cunliffe NA. Coronavirus disease (COVID-19) - impact on vaccine
555 preventable diseases. *Euro Surveill*. 2020;25(18). Epub 2020/05/14. doi: 10.2807/1560-
556 7917.ES.2020.25.18.2000756. PubMed PMID: 32400359; PubMed Central PMCID:
557 PMCPMC7219030.
- 558 6. COVID-19 significantly impacts health services for noncommunicable diseases
559 [Internet]. 2020
- 560 7. Mafham MM, Spata E, Goldacre R, Gair D, Curnow P, Bray M, et al. COVID-19
561 pandemic and admission rates for and management of acute coronary syndromes in England.
562 *Lancet*. 2020;396(10248):381-9. Epub 2020/07/18. doi: 10.1016/S0140-6736(20)31356-8.
563 PubMed PMID: 32679111; PubMed Central PMCID: PMCPMC7429983.
- 564 8. Mehrotra A, Chernew M, Linetsky D, Hatch H, Cutler D, Schneider EC. The Impact of
565 the COVID-19 Pandemic on Outpatient Care: Visits Return to Prepandemic Levels, but Not for
566 All Providers and Patients. Commonwealth Fund, 2020.
- 567 9. CDC. Health Equity Considerations and Racial and Ethnic Minority Groups 2020.
568 Available from: [https://www.cdc.gov/coronavirus/2019-ncov/community/health-equity/race-](https://www.cdc.gov/coronavirus/2019-ncov/community/health-equity/race-ethnicity.html)
569 [ethnicity.html](https://www.cdc.gov/coronavirus/2019-ncov/community/health-equity/race-ethnicity.html).
- 570 10. Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, et al. PRISMA
571 Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. *Ann Intern Med*.
572 2018;169(7):467-73. Epub 2018/09/05. doi: 10.7326/M18-0850. PubMed PMID: 30178033.
- 573 11. Covidence systematic review software, Veritas Health Innovation, Melbourne, Australia.
574 2020. Available from: www.covidence.org.
- 575 12. EndNote X8. Clarivate Analytics 2020. Available from: <https://endnote.com/>.
- 576 13. Ridgway JP, Schmitt J, Friedman E, Taylor M, Devlin S, McNulty M, et al. HIV Care
577 Continuum and COVID-19 Outcomes Among People Living with HIV During the COVID-19
578 Pandemic, Chicago, IL. *AIDS Behav*. 2020;24(10):2770-2. doi: 10.1007/s10461-020-02905-2.
579 PubMed PMID: 32382823.

- 580 14. Spinelli MA, Hickey MD, Glidden DV, Nguyen JQ, Oskarsson JJ, Havlir D, et al. Viral
581 suppression rates in a safety-net HIV clinic in San Francisco destabilized during COVID-19.
582 *Aids*. 2020. doi: 10.1097/qad.0000000000002677. PubMed PMID: 32910069.
- 583 15. Quiros-Roldan E, Magro P, Carriero C, Chiesa A, El Hamad I, Tratta E, et al.
584 Consequences of the COVID-19 pandemic on the continuum of care in a cohort of people living
585 with HIV followed in a single center of Northern Italy. *AIDS Res Ther*. 2020;17(1):59. doi:
586 10.1186/s12981-020-00314-y. PubMed PMID: 33012282.
- 587 16. Luis H, Fridayantara WD, Mahariski P, Wignall FS, Irwanto I, Gedela K. Evolving ART
588 crisis for people living with HIV in Indonesia. *Lancet HIV*. 2020;7(6):e384-e5. doi:
589 10.1016/s2352-3018(20)30138-7. PubMed PMID: 32359421.
- 590 17. Linnemayr S, Jennings Mayo-Wilson L, Saya U, Wagner Z, MacCarthy S, Walukaga S,
591 et al. HIV Care Experiences During the COVID-19 Pandemic: Mixed-Methods Telephone
592 Interviews with Clinic-Enrolled HIV-Infected Adults in Uganda. *AIDS Behav*. 2020:1-12. doi:
593 10.1007/s10461-020-03032-8. PubMed PMID: 32918641.
- 594 18. Rao A, Rucinski K, Jarrett B, Ackerman B, Wallach S, Marcus J, et al. Potential
595 interruptions in HIV prevention and treatment services for gay, bisexual, and other men who
596 have sex with men associated with COVID-19. *MedRxiv*. 2020. doi:
597 10.1101/2020.08.19.20178285.
- 598 19. Nyoni T, Okumu M. COVID-19-Compliant Strategies for Supporting Treatment
599 Adherence Among People Living with HIV in Sub-Saharan Africa. *AIDS Behav*.
600 2020;24(9):2473-6. doi: 10.1007/s10461-020-02888-0. PubMed PMID: 32333204.
- 601 20. Ponticiello M, Mwanga-Amumpaire J, Tushemereirwe P, Nuwagaba G, King R,
602 Sundararajan R. "Everything is a Mess": How COVID-19 is Impacting Engagement with HIV
603 Testing Services in Rural Southwestern Uganda. *AIDS Behav*. 2020;24(11):3006-9. doi:
604 10.1007/s10461-020-02935-w. PubMed PMID: 32451939.
- 605 21. Darcis G, Vaira D, Moutschen M. Impact of coronavirus pandemic and containment
606 measures on HIV diagnosis. *Epidemiol Infect*. 2020;148:e185. doi:
607 10.1017/s0950268820001867. PubMed PMID: 32829742.
- 608 22. Ejima K, Koizumi Y, Yamamoto N, Rosenberg M, Ludema C, Bento AI, et al. HIV
609 testing by public health centers and municipalities, and new HIV cases during the COVID-19
610 pandemic in Japan. *MedRxiv*. 2020. doi: 10.1101/2020.10.16.20213959.
- 611 23. Hammoud MA, Grulich A, Holt M, Maher L, Murphy D, Jin F, et al. Substantial decline
612 in use of HIV pre-exposure prophylaxis (PrEP) following introduction of COVID-19 physical
613 distancing restrictions in Australia: Results from a prospective observational study of gay and
614 bisexual men. *J Acquir Immune Defic Syndr*. 2020. doi: 10.1097/qai.0000000000002514.
615 PubMed PMID: 33027151.
- 616 24. Chow EPF, Hocking JS, Ong JJ, Schmidt T, Buchanan A, Rodriguez E, et al. Changing
617 the Use of HIV Pre-exposure Prophylaxis Among Men Who Have Sex With Men During the
618 COVID-19 Pandemic in Melbourne, Australia. *Open Forum Infect Dis*. 2020;7(7):ofaa275. doi:
619 10.1093/ofid/ofaa275. PubMed PMID: 32704518.
- 620 25. Sánchez-Rubio J, Vélez-Díaz-Pallarés M, Rodríguez González C, Sanmartin Fenollera P,
621 García Yubero C, Fernández-Pacheco García-Valdecasas M. HIV postexposure prophylaxis
622 during the COVID-19 pandemic: experience from Madrid. *Sex Transm Infect*. 2020. doi:
623 10.1136/sextrans-2020-054680. PubMed PMID: 32680842.

- 624 26. Chow EPF, Hocking JS, Ong JJ, Phillips TR, Fairley CK. Postexposure prophylaxis
625 during COVID-19 lockdown in Melbourne, Australia. *Lancet HIV*. 2020;7(8):e528-e9. doi:
626 10.1016/s2352-3018(20)30204-6. PubMed PMID: 32687796.
- 627 27. Qiao S, Li Z, Weissman S, Li X, Olatosi B, Davis C, et al. Disparity in HIV Service
628 Interruption in the Outbreak of COVID-19 in South Carolina. *AIDS Behav*. 2020:1-9. doi:
629 10.1007/s10461-020-03013-x. PubMed PMID: 32856176.
- 630 28. Gichuna S, Hassan R, Sanders T, Campbell R, Mutonyi M, Mwangi P. Access to
631 Healthcare in a time of COVID-19: Sex Workers in Crisis in Nairobi, Kenya. *Glob Public*
632 *Health*. 2020;15(10):1430-42. doi: 10.1080/17441692.2020.1810298. PubMed PMID: 32816628.
- 633 29. Santos GM, Ackerman B, Rao A, Wallach S, Ayala G, Lamontagne E, et al. Economic,
634 Mental Health, HIV Prevention and HIV Treatment Impacts of COVID-19 and the COVID-19
635 Response on a Global Sample of Cisgender Gay Men and Other Men Who Have Sex with Men.
636 *AIDS Behav*. 2020:1-11. doi: 10.1007/s10461-020-02969-0. PubMed PMID: 32654021.
- 637 30. Sanchez TH, Zlotorzynska M, Rai M, Baral SD. Characterizing the Impact of COVID-19
638 on Men Who Have Sex with Men Across the United States in April, 2020. *AIDS Behav*.
639 2020;24(7):2024-32. doi: 10.1007/s10461-020-02894-2. PubMed PMID: 32350773.
- 640 31. Rogers BG, Arnold T, Schierberl Scherr A, Strong SH, Holcomb R, Daley Ndoeye C, et
641 al. Adapting Substance Use Treatment for HIV Affected Communities During COVID-19:
642 Comparisons Between a Sexually Transmitted Infections (STI) Clinic and a Local Community
643 Based Organization. *AIDS Behav*. 2020;24(11):2999-3002. doi: 10.1007/s10461-020-02933-y.
644 PubMed PMID: 32462344.
- 645 32. Mgbako O, Miller EH, Santoro AF, Remien RH, Shalev N, Olender S, et al. COVID-19,
646 Telemedicine, and Patient Empowerment in HIV Care and Research. *AIDS Behav*.
647 2020;24(7):1990-3. doi: 10.1007/s10461-020-02926-x. PubMed PMID: 32440970.
- 648 33. Hoagland B, Torres TS, Bezerra DRB, Geraldo K, Pimenta C, Veloso VG, et al.
649 Telemedicine as a tool for PrEP delivery during the COVID-19 pandemic in a large HIV
650 prevention service in Rio de Janeiro-Brazil. *Braz J Infect Dis*. 2020;24(4):360-4. doi:
651 10.1016/j.bjid.2020.05.004. PubMed PMID: 32504552.
- 652 34. Armstrong WS, Agwu AL, Barrette EP, Ignacio RB, Chang JJ, Colasanti JA, et al.
653 Innovations in HIV care delivery during the COVID-19 pandemic: Policies to strengthen the
654 Ending the Epidemic Initiative - A Policy Paper of the Infectious Diseases Society of America
655 and the HIV Medicine Association. *Clin Infect Dis*. 2020. doi: 10.1093/cid/ciaa1532. PubMed
656 PMID: 33035296.
- 657 35. Giuliani M, Donà MG, La Malfa A, Pasquantonio MS, Pimpinelli F, Cristaudo A, et al.
658 Ensuring retention in care for people living with HIV during the COVID-19 pandemic in Rome,
659 Italy. *Sex Transm Infect*. 2020. doi: 10.1136/sextrans-2020-054650. PubMed PMID: 33046581.
- 660 36. Dourado I, Magno L, Soares F, Massa P, Nunn A, Dalal S, et al. Adapting to the COVID-
661 19 Pandemic: Continuing HIV Prevention Services for Adolescents Through Telemonitoring,
662 Brazil. *AIDS Behav*. 2020;24(7):1994-9. doi: 10.1007/s10461-020-02927-w. PubMed PMID:
663 32440973.
- 664 37. Menza TW, Garai J, Ferrer J, Hecht J. Rapid Uptake of Home-Based HIV Self-testing
665 During Social Distancing for SARS-CoV2 Infection in Oregon. *AIDS Behav*. 2020:1-4. doi:
666 10.1007/s10461-020-02959-2. PubMed PMID: 32594272.
- 667 38. Mhango M, Chitungo I, Dzinamarira T. COVID-19 Lockdowns: Impact on Facility-
668 Based HIV Testing and the Case for the Scaling Up of Home-Based Testing Services in Sub-

- 669 Saharan Africa. *AIDS Behav.* 2020;24(11):3014-6. doi: 10.1007/s10461-020-02939-6. PubMed
670 PMID: 32488551.
- 671 39. Odinga MM, Kuria S, Muindi O, Mwakazi P, Njraini M, Melon M, et al. HIV testing
672 amid COVID-19: community efforts to reach men who have sex with men in three Kenyan
673 counties. *Gates Open Res.* 2020;4:117. doi: 10.12688/gatesopenres.13152.1. PubMed PMID:
674 32954217.
- 675 40. Brey Z, Mash R, Goliath C, Roman D. Home delivery of medication during Coronavirus
676 disease 2019, Cape Town, South Africa: Short report. *Afr J Prim Health Care Fam Med.*
677 2020;12(1):e1-e4. doi: 10.4102/phcfm.v12i1.2449. PubMed PMID: 32501022.
- 678 41. Kay ES, Musgrove K. From HIV to Coronavirus: AIDS Service Organizations
679 Adaptative Responses to COVID-19, Birmingham, Alabama. *AIDS Behav.* 2020;24(9):2461-2.
680 doi: 10.1007/s10461-020-02879-1. PubMed PMID: 32333206.
- 681 42. Mohammed H, Oljira L, Roba KT, Yimer G, Fekadu A, Manyazewal T. Containment of
682 COVID-19 in Ethiopia and implications for tuberculosis care and research. *Infectious Diseases
683 of Poverty.* 2020;9(1):131. doi: 10.1186/s40249-020-00753-9.
- 684 43. Abdool Karim Q, Abdool Karim SS. COVID-19 affects HIV and tuberculosis care.
685 *Science.* 2020;369(6502):366-8. Epub 2020/07/25. doi: 10.1126/science.abd1072. PubMed
686 PMID: 32703860.
- 687 44. Togun T, Kampmann B, Stoker NG, Lipman M. Anticipating the impact of the COVID-
688 19 pandemic on TB patients and TB control programmes. *Annals of Clinical Microbiology and
689 Antimicrobials.* 2020;19(1):21. doi: 10.1186/s12941-020-00363-1.
- 690 45. Ahmed SAKS, Ajisola M, Azeem K, Bakibinga P, Chen Y-F, Choudhury NN, et al.
691 Impact of the societal response to COVID-19 on access to healthcare for non-COVID-19 health
692 issues in slum communities of Bangladesh, Kenya, Nigeria and Pakistan: results of pre-COVID
693 and COVID-19 lockdown stakeholder engagements. *BMJ Global Health.* 2020;5(8):e003042.
694 doi: 10.1136/bmjgh-2020-003042.
- 695 46. Migliori GB, Thong PM, Akkerman O, Alffenaar J-W, Álvarez-Navascués F, Assao-
696 Neino MM, et al. Worldwide Effects of Coronavirus Disease Pandemic on Tuberculosis
697 Services, January–April 2020. *Emerging Infectious Disease journal.* 2020;26(11):2709. doi:
698 10.3201/eid2611.203163.
- 699 47. Shen X, Sha W, Yang C, Pan Q, Cohen T, Chen S, et al. Continuity of services for
700 patients with tuberculosis in China in the COVID-19 era. *medRxiv.* 2020:2020.07.16.20150292.
701 doi: 10.1101/2020.07.16.20150292.
- 702 48. Liu Q, Lu P, Shen Y, Li C, Wang J, Zhu L, et al. Collateral Impact of the Coronavirus
703 Disease 2019 (COVID-19) Pandemic on Tuberculosis Control in Jiangsu Province, China.
704 *Clinical Infectious Diseases.* 2020. doi: 10.1093/cid/ciaa1289.
- 705 49. Kwak N, Hwang S-S, Yim J-J. Effect of COVID-19 on Tuberculosis Notification, South
706 Korea. *Emerging Infectious Disease journal.* 2020;26(10):2506. doi: 10.3201/eid2610.202782.
- 707 50. Adewole OO. Impact of COVID-19 on TB care: experiences of a treatment centre in
708 Nigeria. *Int J Tuberc Lung Dis.* 2020;24(9):981-2. Epub 2020/11/07. doi: 10.5588/ijtld.20.0418.
709 PubMed PMID: 33156771.
- 710 51. Louie JK, Reid M, Stella J, Agraz-Lara R, Graves S, Chen L, et al. A decrease in
711 tuberculosis evaluations and diagnoses during the COVID-19 pandemic. *Int J Tuberc Lung Dis.*
712 2020;24(8):860-2. Epub 2020/09/12. doi: 10.5588/ijtld.20.0364. PubMed PMID: 32912395.
- 713 52. Buonsenso D, Iodice F, Sorba Biala J, Goletti D. COVID-19 effects on tuberculosis care
714 in Sierra Leone. *Pulmonology.* 2020. doi: <https://doi.org/10.1016/j.pulmoe.2020.05.013>.

- 715 53. Chen H, Zhang K. Insight into the impact of the COVID-19 epidemic on tuberculosis
716 burden in China. *European Respiratory Journal*. 2020;56(3):2002710. doi:
717 10.1183/13993003.02710-2020.
- 718 54. Chiang C-Y, Islam T, Xu C, Chinnayah T, Garfin AMC, Rahevar K, et al. The impact of
719 COVID-19 and the restoration of tuberculosis services in the Western Pacific Region. *European*
720 *Respiratory Journal*. 2020;56(4):2003054. doi: 10.1183/13993003.03054-2020.
- 721 55. Datta B, Jaiswal A, Goyal P, Prakash A, Tripathy JP, Trehan N. The untimely demise of
722 the TB Free block model in the wake of coronavirus disease 2019 in India. *Transactions of The*
723 *Royal Society of Tropical Medicine and Hygiene*. 2020;114(11):789-91. doi:
724 10.1093/trstmh/traa067.
- 725 56. Komiya K, Yamasue M, Takahashi O, Hiramatsu K, Kadota JI, Kato S. The COVID-19
726 pandemic and the true incidence of Tuberculosis in Japan. *J Infect*. 2020;81(3):e24-e5. Epub
727 2020/07/11. doi: 10.1016/j.jinf.2020.07.004. PubMed PMID: 32650109; PubMed Central
728 PMCID: PMCPMC7338857.
- 729 57. Lai CC, Yu WL. The COVID-19 pandemic and tuberculosis in Taiwan. *J Infect*.
730 2020;81(2):e159-e61. Epub 2020/06/14. doi: 10.1016/j.jinf.2020.06.014. PubMed PMID:
731 32534000; PubMed Central PMCID: PMCPMC7286835.
- 732 58. Liu Q, Lu P, Shen Y, Li C, Wang J, Zhu L, et al. Collateral Impact of the Covid-19
733 Pandemic on Tuberculosis Control in Jiangsu Province, China. *Clin Infect Dis*. 2020. Epub
734 2020/08/29. doi: 10.1093/cid/ciaa1289. PubMed PMID: 32857838; PubMed Central PMCID:
735 PMCPMC7499510.
- 736 59. Khan MS, Rego S, Rajal JB, Bond V, Fatima RK, Isani AK, et al. Mitigating the impact
737 of COVID-19 on tuberculosis and HIV services: a cross-sectional survey of 669 health
738 professionals in 64 low and middle-income countries. *medRxiv*. 2020:2020.10.08.20207969. doi:
739 10.1101/2020.10.08.20207969.
- 740 60. Cronin AM, Railey S, Fortune D, Wegener DH, Davis JB. Notes from the Field: Effects
741 of the COVID-19 Response on Tuberculosis Prevention and Control Efforts - United States,
742 March-April 2020. *MMWR Morb Mortal Wkly Rep*. 2020;69(29):971-2. Epub 2020/07/24. doi:
743 10.15585/mmwr.mm6929a4. PubMed PMID: 32701944; PubMed Central PMCID:
744 PMCPMC7377818 Journal Editors form for disclosure of potential conflicts of interest. No
745 potential conflicts of interest were disclosed.
- 746 61. Husain AA, Monaghan TM, Kashyap RS. Impact of COVID-19 pandemic on
747 tuberculosis care in India. *Clin Microbiol Infect*. 2020. Epub 2020/08/22. doi:
748 10.1016/j.cmi.2020.08.014. PubMed PMID: 32822881; PubMed Central PMCID:
749 PMCPMC7434422.
- 750 62. Ribeiro VST, Telles JP, Tuon FF. Concerns about COVID-19 and tuberculosis in Brazil:
751 Social and public health impacts. *Enfermedades Infecciosas y Microbiología Clínica*. 2020. doi:
752 <https://doi.org/10.1016/j.eimc.2020.08.013>.
- 753 63. Chandir S, Siddiqi DA, Mehmood M, Setayesh H, Siddique M, Mirza A, et al. Impact of
754 COVID-19 pandemic response on uptake of routine immunizations in Sindh, Pakistan: An
755 analysis of provincial electronic immunization registry data. *Vaccine*. 2020;38(45):7146-55. doi:
756 <https://doi.org/10.1016/j.vaccine.2020.08.019>.
- 757 64. Glaziou P. Predicted impact of the COVID-19 pandemic on global tuberculosis deaths in
758 2020. *medRxiv*. 2020:2020.04.28.20079582. doi: 10.1101/2020.04.28.20079582.

- 759 65. McQuaid CF, McCreesh N, Read JM, Sumner T, Houben RMGJ, White RG, et al. The
760 potential impact of COVID-19-related disruption on tuberculosis burden. *European Respiratory*
761 *Journal*. 2020;56(2):2001718. doi: 10.1183/13993003.01718-2020.
- 762 66. Cilloni L, Fu H, Vesga JF, Dowdy D, Pretorius C, Ahmedov S, et al. The potential
763 impact of the COVID-19 pandemic on the tuberculosis epidemic a modelling analysis.
764 *EClinicalMedicine*. 2020;28:100603. Epub 2020/11/03. doi: 10.1016/j.eclinm.2020.100603.
765 PubMed PMID: 33134905; PubMed Central PMCID: PMCPMC7584493.
- 766 67. Hogan AB, Jewell BL, Sherrard-Smith E, Vesga JF, Watson OJ, Whittaker C, et al.
767 Potential impact of the COVID-19 pandemic on HIV, tuberculosis, and malaria in low-income
768 and middle-income countries: a modelling study. *Lancet Glob Health*. 2020;8(9):e1132-e41. doi:
769 10.1016/s2214-109x(20)30288-6. PubMed PMID: 32673577.
- 770 68. Cox V, Wilkinson L, Grimsrud A, Hughes J, Reuter A, Conradie F, et al. Critical changes
771 to services for TB patients during the COVID-19 pandemic. *The International Journal of*
772 *Tuberculosis and Lung Disease*. 2020;24(5):542-4. doi: 10.5588/ijtld.20.0205.
773
- 774 69. Malik AA, Safdar N, Chandir S, Khan U, Khowaja S, Riaz N, et al. Tuberculosis control
775 and care in the era of COVID-19. *Health Policy and Planning*. 2020;35(8):1130-2. doi:
776 10.1093/heapol/czaa109.
- 777 70. Bell D, Hansen KS, Kiragga AN, Kambugu A, Kissa J, Mbonye AK. Predicting the
778 Impact of COVID-19 and the Potential Impact of the Public Health Response on Disease Burden
779 in Uganda. *Am J Trop Med Hyg*. 2020;103(3):1191-7. doi: 10.4269/ajtmh.20-0546. PubMed
780 PMID: 32705975.
- 781 71. Guerra CA, Tresor Donfack O, Motobe Vaz L, Mba Nlang JA, Nze Nchama LO, Mba
782 Eyono JN, et al. Malaria vector control in sub-Saharan Africa in the time of COVID-19: no room
783 for complacency. *BMJ Glob Health*. 2020;5(9). doi: 10.1136/bmjgh-2020-003880. PubMed
784 PMID: 32938611.
- 785 72. Rogerson SJ, Beeson JG, Laman M, Poespoprodjo JR, William T, Simpson JA, et al.
786 Identifying and combating the impacts of COVID-19 on malaria. *BMC Med*. 2020;18(1):239.
787 doi: 10.1186/s12916-020-01710-x. PubMed PMID: 32727467.
- 788 73. Mejia R, Hotez P, Bottazzi ME. Global COVID-19 Efforts as the Platform to Achieving
789 the Sustainable Development Goals. *Curr Trop Med Rep*. 2020:1-5. doi: 10.1007/s40475-020-
790 00209-y. PubMed PMID: 32844081.
- 791 74. Robinson EF, Moulder JK, Zerden ML, Miller AM, Zite NB. Preserving and advocating
792 for essential care for women during the coronavirus disease 2019 pandemic. *Am J Obstet*
793 *Gynecol*. 2020;223(2):219-20.e1. doi: 10.1016/j.ajog.2020.05.022. PubMed PMID: 32405073.
- 794 75. Nghochuzie NN, Olwal CO, Udoakang AJ, Amenga-Etego LN, Amambua-Ngwa A.
795 Pausing the Fight Against Malaria to Combat the COVID-19 Pandemic in Africa: Is the Future
796 of Malaria Bleak? *Front Microbiol*. 2020;11:1476. doi: 10.3389/fmicb.2020.01476. PubMed
797 PMID: 32625198.
- 798 76. Weiss DJ, Bertozzi-Villa A, Rumisha SF, Amratia P, Arambepola R, Battle KE, et al.
799 Indirect effects of the COVID-19 pandemic on malaria intervention coverage, morbidity, and
800 mortality in Africa: a geospatial modelling analysis. *Lancet Infect Dis*. 2020. doi:
801 10.1016/s1473-3099(20)30700-3. PubMed PMID: 32971006.
- 802 77. Torres K, Alava F, Soto-Calle V, Llanos-Cuentas A, Rodriguez H, Llacsahuanga L, et al.
803 Malaria Situation in the Peruvian Amazon during the COVID-19 Pandemic. *Am J Trop Med*
804 *Hyg*. 2020. doi: 10.4269/ajtmh.20-0889. PubMed PMID: 32885776.

- 805 78. Buonsenso D, Cinicola B, Kallon MN, Iodice F. Child Healthcare and Immunizations in
806 Sub-Saharan Africa During the COVID-19 Pandemic. *Front Pediatr*. 2020;8:517. doi:
807 10.3389/fped.2020.00517. PubMed PMID: 32850565.
- 808 79. Beshir KB, Grignard L, Hajissa K, Mohammed A, Nurhusein AM, Ishengoma DS, et al.
809 Emergence of Undetectable Malaria Parasites: A Threat under the Radar amid the COVID-19
810 Pandemic? *Am J Trop Med Hyg*. 2020;103(2):558-60. doi: 10.4269/ajtmh.20-0467. PubMed
811 PMID: 32553046.
- 812 80. Chanda-Kapata P, Kapata N, Zumla A. COVID-19 and malaria: A symptom screening
813 challenge for malaria endemic countries. *Int J Infect Dis*. 2020;94:151-3. doi:
814 10.1016/j.ijid.2020.04.007. PubMed PMID: 32344326.
- 815 81. Zawawi A, Alghanmi M, Alsaady I, Gattan H, Zakai H, Couper K. The impact of
816 COVID-19 pandemic on malaria elimination. *Parasite Epidemiol Control*. 2020:e00187. doi:
817 10.1016/j.parepi.2020.e00187. PubMed PMID: 33102823.
- 818 82. Bull-Otterson L, Gray EB, Budnitz DS, Strosnider HM, Schieber LZ, Courtney J, et al.
819 Hydroxychloroquine and Chloroquine Prescribing Patterns by Provider Specialty Following
820 Initial Reports of Potential Benefit for COVID-19 Treatment - United States, January-June 2020.
821 *MMWR Morb Mortal Wkly Rep*. 2020;69(35):1210-5. doi: 10.15585/mmwr.mm6935a4.
822 PubMed PMID: 32881845.
- 823 83. Mvumbi DM. Mass intake of hydroxychloroquine or chloroquine in the present context
824 of the Covid-19 outbreak: Possible consequences in endemic malaria settings. *Med Hypotheses*.
825 2020;143:109912. doi: 10.1016/j.mehy.2020.109912. PubMed PMID: 32498009.
- 826 84. Abena PM, Decloedt EH, Bottieau E, Suleman F, Adejumo P, Sam-Agudu NA, et al.
827 Chloroquine and Hydroxychloroquine for the Prevention or Treatment of COVID-19 in Africa:
828 Caution for Inappropriate Off-label Use in Healthcare Settings. *Am J Trop Med Hyg*.
829 2020;102(6):1184-8. doi: 10.4269/ajtmh.20-0290. PubMed PMID: 32323646.
- 830 85. Cox S. To dispense or not to dispense: Lessons to be learnt from ethical challenges faced
831 by pharmacists in the COVID-19 pandemic. *Dev World Bioeth*. 2020. doi: 10.1111/dewb.12284.
832 PubMed PMID: 32844516.
- 833 86. Rodriguez-Valero N, Vera I, Torralvo MR, De Alba T, Ferrer E, Camprubi D, et al.
834 Malaria prophylaxis approach during COVID-19 pandemic. *Travel Med Infect Dis*.
835 2020;101716. doi: 10.1016/j.tmaid.2020.101716. PubMed PMID: 32360423.
- 836 87. Starrs AM, Ezeh AC, Barker G, Basu A, Bertrand JT, Blum R, et al. Accelerate progress-
837 sexual and reproductive health and rights for all: report of the Guttmacher-Lancet Commission.
838 *Lancet*. 2018;391(10140):2642-92. Epub 2018/05/14. doi: 10.1016/S0140-6736(18)30293-9.
839 PubMed PMID: 29753597.
- 840 88. Robertson T, Carter ED, Chou VB, Stegmuller AR, Jackson BD, Tam Y, et al. Early
841 estimates of the indirect effects of the COVID-19 pandemic on maternal and child mortality in
842 low-income and middle-income countries: a modelling study. *Lancet Glob Health*.
843 2020;8(7):e901-e8. PubMed PMID: 32405459.
- 844 89. Riley T, Sully E, Ahmed Z, Biddlecom A. Estimates of the Potential Impact of the
845 COVID-19 Pandemic on Sexual and Reproductive Health In Low- and Middle-Income
846 Countries. *Int Perspect Sex Reprod Health*. 2020;46:73-6. Epub 2020/04/29. doi:
847 10.1363/46e9020. PubMed PMID: 32343244.
- 848 90. Dasgupta A, Kantorova V, Ueffing P. The impact of the COVID-19 crisis on meeting
849 needs for family planning: a global scenario by contraceptive methods used. *Gates Open Res*.

- 850 2020;4:102. Epub 2020/12/19. doi: 10.12688/gatesopenres.13148.2. PubMed PMID: 33330836;
851 PubMed Central PMCID: PMCPMC7720714.
- 852 91. Weinberger M, Hayes B, White J, Skibiak J. Doing Things Differently: What It Would
853 Take to Ensure Continued Access to Contraception During COVID-19. *Glob Health Sci Pract.*
854 2020;8(2):169-75. Epub 2020/06/21. doi: 10.9745/GHSP-D-20-00171. PubMed PMID:
855 32561528; PubMed Central PMCID: PMCPMC7326519.
- 856 92. Purdy C. How will COVID-19 affect global access to contraceptives—and what can we
857 do about it? *Devex.* 2020.
- 858 93. Marie Stopes International (MSI). Resilience, adaptation and action. MSI's response to
859 COVID-19. MSI, August, 2020.
- 860 94. Siedner MJ, Kraemer JD, Meyer MJ, Harling G, Mngomezulu T, Gabela P, et al. Access
861 to primary healthcare during lockdown measures for COVID-19 in rural South Africa: an
862 interrupted time series analysis. *BMJ Open.* 2020;10(10):e043763. doi: 10.1136/bmjopen-2020-
863 043763. PubMed PMID: 33020109.
- 864 95. Coombe J, Kong F, Bittleston H, Williams H, Tomnay J, Vaisey A, et al. The impact of
865 COVID-19 on the reproductive health of people living in Australia: findings from an online
866 survey. *medRxiv.* 2020:2020.08.10.20172163. doi: 10.1101/2020.08.10.20172163.
- 867 96. Shikuku DN, Nyaoke I, Gichuru S, Maina O, Eyinda M, Godia P, et al. Early indirect
868 impact of COVID-19 pandemic on utilization and outcomes of reproductive, maternal, newborn,
869 child and adolescent health services in Kenya. *medRxiv.* 2020:2020.09.09.20191247. doi:
870 10.1101/2020.09.09.20191247.
- 871 97. Wangamati CK, Sundby J. The ramifications of COVID-19 on maternal health in Kenya.
872 *Sex Reprod Health Matters.* 2020;28(1):1804716. doi: 10.1080/26410397.2020.1804716.
873 PubMed PMID: 32896231.
- 874 98. Skuster P, Khanal RC, Nyamato E. Relics of imperialism: US foreign policy on abortion
875 in the COVID era. *Sex Reprod Health Matters.* 2020;28(3):1824319. doi:
876 10.1080/26410397.2020.1824319. PubMed PMID: 33048026.
- 877 99. Abdela SG, Berhanu AB, Ferede LM, van Griensven J. Essential Healthcare Services in
878 the Face of COVID-19 Prevention: Experiences from a Referral Hospital in Ethiopia. *Am J Trop*
879 *Med Hyg.* 2020;103(3):1198-200. doi: 10.4269/ajtmh.20-0464. PubMed PMID: 32762799.
- 880 100. Yuksel B, Ozgor F. Effect of the COVID-19 pandemic on female sexual behavior. *Int J*
881 *Gynaecol Obstet.* 2020;150(1):98-102. doi: 10.1002/ijgo.13193. PubMed PMID: 32392400.
- 882 101. Caruso S, Rapisarda AMC, Minona P. Sexual activity and contraceptive use during social
883 distancing and self-isolation in the COVID-19 pandemic. *Eur J Contracept Reprod Health Care.*
884 2020:1-4. doi: 10.1080/13625187.2020.1830965. PubMed PMID: 33044107.
- 885 102. Thomson-Glover R, Hamlett H, Weston D, Ashby J. Coronavirus (COVID-19) and
886 young people's sexual health. *Sex Transm Infect.* 2020;96(7):473-4. doi: 10.1136/sextrans-2020-
887 054699. PubMed PMID: 33077611.
- 888 103. Ahmed A. How the COVID-19 response is altering the legal and regulatory landscape on
889 abortion. *J Law Biosci.* 2020;7(1):lsaa012. doi: 10.1093/jlb/lsaa012. PubMed PMID: 32728459.
- 890 104. Fulcher IR, Neill S, Bharadwa S, Goldberg AB, Janiak E. State and federal abortion
891 restrictions increase risk of COVID-19 exposure by mandating unnecessary clinic visits.
892 *Contraception.* 2020. doi: 10.1016/j.contraception.2020.08.017. PubMed PMID: 32905791.
- 893 105. Gildner TE, Thayer ZM. Birth plan alterations among American women in response to
894 COVID-19. *Health Expect.* 2020;23(4):969-71. doi: 10.1111/hex.13077. PubMed PMID:
895 32449262.

- 896 106. Ashish K, Gurung R, Kinney MV, Sunny AK, Moinuddin M, Basnet O, et al. Effect of
897 the COVID-19 pandemic response on intrapartum care, stillbirth, and neonatal mortality
898 outcomes in Nepal: a prospective observational study. *The Lancet Global health*.
899 2020;8(10):e1273-e81. Epub 2020/08/10. doi: 10.1016/S2214-109X(20)30345-4. PubMed
900 PMID: 32791117.
- 901 107. Coxon K, Turienzo CF, Kweekel L, Goodarzi B, Brigante L, Simon A, et al. The impact
902 of the coronavirus (COVID-19) pandemic on maternity care in Europe. *Midwifery*.
903 2020;88:102779. doi: 10.1016/j.midw.2020.102779. PubMed PMID: 32600862.
- 904 108. Davis-Floyd R, Gutschow K, Schwartz DA. Pregnancy, Birth and the COVID-19
905 Pandemic in the United States. *Med Anthropol*. 2020;39(5):413-27. doi:
906 10.1080/01459740.2020.1761804. PubMed PMID: 32406755.
- 907 109. Graham WJ, Afolabi B, Benova L, Campbell OMR, Filippi V, Nakimuli A, et al.
908 Protecting hard-won gains for mothers and newborns in low-income and middle-income
909 countries in the face of COVID-19: call for a service safety net. *BMJ Glob Health*. 2020;5(6).
910 doi: 10.1136/bmjgh-2020-002754. PubMed PMID: 32499220.
- 911 110. Pallangyo E, Nakate MG, Maina R, Fleming V. The impact of covid-19 on midwives'
912 practice in Kenya, Uganda and Tanzania: A reflective account. *Midwifery*. 2020;89:102775. doi:
913 10.1016/j.midw.2020.102775. PubMed PMID: 32526597.
- 914 111. Rimmer MP, Al Wattar BH. Provision of obstetrics and gynaecology services during the
915 COVID-19 pandemic: a survey of junior doctors in the UK National Health Service. *Bjog*.
916 2020;127(9):1123-8. doi: 10.1111/1471-0528.16313. PubMed PMID: 32460422.
- 917 112. Rochelson B, Nimaroff M, Combs A, Schwartz B, Meirowitz N, Vohra N, et al. The care
918 of pregnant women during the COVID-19 pandemic - response of a large health system in
919 metropolitan New York. *J Perinat Med*. 2020;48(5):453-61. doi: 10.1515/jpm-2020-0175.
920 PubMed PMID: 32432568.
- 921 113. Semaan A, Audet C, Huysmans E, Afolabi B, Assarag B, Banke-Thomas A, et al. Voices
922 from the frontline: findings from a thematic analysis of a rapid online global survey of maternal
923 and newborn health professionals facing the COVID-19 pandemic. *BMJ Global Health*.
924 2020;5(6):e002967. doi: 10.1136/bmjgh-2020-002967.
- 925 114. Benova L, Sarkar ND, Fasehun LO, Semaan A, Affun-Adegbulu C. A call to action:
926 Documenting and sharing solutions and adaptations in sexual, reproductive, maternal and
927 newborn health care provision during the COVID-19 pandemic. *Sex Reprod Health Matters*.
928 2020:1-5. doi: 10.1080/26410397.2020.1838054. PubMed PMID: 33073726.
- 929 115. Bateson DJ, Lohr PA, Norman WV, Moreau C, Gemzell-Danielsson K, Blumenthal PD,
930 et al. The impact of COVID-19 on contraception and abortion care policy and practice:
931 experiences from selected countries. *BMJ Sex Reprod Health*. 2020;46(4):241-3. doi:
932 10.1136/bmjsex-2020-200709. PubMed PMID: 32788180.
- 933 116. Cohen MA, Powell AM, Coleman JS, Keller JM, Livingston A, Anderson JR. Special
934 ambulatory gynecologic considerations in the era of coronavirus disease 2019 (COVID-19) and
935 implications for future practice. *Am J Obstet Gynecol*. 2020;223(3):372-8. doi:
936 10.1016/j.ajog.2020.06.006. PubMed PMID: 32522513.
- 937 117. Ferreira-Filho ES, de Melo NR, Sorpreso ICE, Bahamondes L, Simões RDS, Soares-
938 Júnior JM, et al. Contraception and reproductive planning during the COVID-19 pandemic.
939 *Expert Rev Clin Pharmacol*. 2020;13(6):615-22. doi: 10.1080/17512433.2020.1782738. PubMed
940 PMID: 32538185.

- 941 118. Moreau C, Shankar M, Glasier A, Cameron S, Gemzell-Danielsson K. Abortion
942 regulation in Europe in the era of COVID-19: a spectrum of policy responses. *BMJ Sex Reprod*
943 *Health*. 2020. doi: 10.1136/bmjsex-2020-200724. PubMed PMID: 33093040.
- 944 119. Jones RK, Lindberg L, Witwer E. COVID-19 Abortion Bans and Their Implications for
945 Public Health. *Perspect Sex Reprod Health*. 2020. doi: 10.1363/psrh.12139. PubMed PMID:
946 32408393.
- 947 120. Aiken ARA, Starling JE, Gomperts R, Tec M, Scott JG, Aiken CE. Demand for Self-
948 Managed Online Telemedicine Abortion in the United States During the Coronavirus Disease
949 2019 (COVID-19) Pandemic. *Obstet Gynecol*. 2020;136(4):835-7. doi:
950 10.1097/aog.0000000000004081. PubMed PMID: 32701762.
- 951 121. Caruana-Finkel L. Abortion in the time of COVID-19: perspectives from Malta. *Sex*
952 *Reprod Health Matters*. 2020;28(1):1780679. doi: 10.1080/26410397.2020.1780679. PubMed
953 PMID: 32516072.
- 954 122. Cioffi A, Cioffi F, Rinaldi R. COVID-19 and abortion: The importance of guaranteeing a
955 fundamental right. *Sex Reprod Healthc*. 2020;25:100538. doi: 10.1016/j.srhc.2020.100538.
956 PubMed PMID: 32534228.
- 957 123. Aiken ARA, Starling JE, Gomperts R, Scott JG, Aiken C. Demand for Self-Managed
958 Online Telemedicine Abortion in Eight European Countries During the COVID-19 Pandemic: A
959 Regression Discontinuity Analysis. *medRxiv*. 2020:2020.09.15.20195222. doi:
960 10.1101/2020.09.15.20195222.
- 961 124. Erlank CP, Lord J, Church K. Early medical abortion using telemedicine – acceptability
962 to patients. *medRxiv*. 2020:2020.11.11.20229377. doi: 10.1101/2020.11.11.20229377.
- 963 125. Nagata JM, Seligman HK, Weiser SD. Perspective: The Convergence of Coronavirus
964 Disease 2019 (COVID-19) and Food Insecurity in the United States. *Adv Nutr*. 2020. doi:
965 10.1093/advances/nmaa126. PubMed PMID: 32970098.
- 966 126. Kalu B. COVID-19 in Nigeria: a disease of hunger. *Lancet Respir Med*. 2020;8(6):556-7.
967 doi: 10.1016/s2213-2600(20)30220-4. PubMed PMID: 32359414.
- 968 127. Brizi A, Biraglia A. "Do I have enough food?" How need for cognitive closure and
969 gender impact stockpiling and food waste during the COVID-19 pandemic: A cross-national
970 study in India and the United States of America. *Pers Individ Dif*. 2021;168:110396. doi:
971 10.1016/j.paid.2020.110396. PubMed PMID: 32982000.
- 972 128. Heck S, Campos H, Barker I, Okello JJ, Baral A, Boy E, et al. Resilient agri-food
973 systems for nutrition amidst COVID-19: evidence and lessons from food-based approaches to
974 overcome micronutrient deficiency and rebuild livelihoods after crises. *Food Secur*.
975 2020;12(4):823-30. doi: 10.1007/s12571-020-01067-2. PubMed PMID: 32839664.
- 976 129. Kabir M, Saqib MAN, Zaid M, Ahmed H, Afzal MS. COVID-19, economic impact and
977 child mortality: A global concern. *Clin Nutr*. 2020;39(7):2322-3. doi:
978 10.1016/j.clnu.2020.05.027. PubMed PMID: 32499056.
- 979 130. Lobascio F, Caccialanza R, Monaco T, Cereda E, Secondino S, Masi S, et al. Providing
980 nutritional care to cancer patients during the COVID-19 pandemic: an Italian perspective.
981 *Support Care Cancer*. 2020;28(9):3987-9. doi: 10.1007/s00520-020-05557-z. PubMed PMID:
982 32495030.
- 983 131. Masonbrink AR, Hurley E. Advocating for Children During the COVID-19 School
984 Closures. *Pediatrics*. 2020;146(3). doi: 10.1542/peds.2020-1440. PubMed PMID: 32554517.
- 985 132. Mayurasakorn K, Pinsawas B, Mongkolsucharitkul P, Sranacharoenpong K, Damapong
986 SN. School closure, COVID-19 and lunch programme: Unprecedented undernutrition crisis in

- 987 low-middle income countries. *J Paediatr Child Health*. 2020;56(7):1013-7. doi:
988 10.1111/jpc.15018. PubMed PMID: 32619327.
- 989 133. Akseer N, Kandru G, Keats EC, Bhutta ZA. COVID-19 pandemic and mitigation
990 strategies: implications for maternal and child health and nutrition. *Am J Clin Nutr*.
991 2020;112(2):251-6. doi: 10.1093/ajcn/nqaa171. PubMed PMID: 32559276.
- 992 134. Panthi B, Khanal P, Dahal M, Maharjan S, Nepal S. An urgent call to address the
993 nutritional status of women and children in Nepal during COVID-19 crises. *Int J Equity Health*.
994 2020;19(1):87. doi: 10.1186/s12939-020-01210-7. PubMed PMID: 32503613.
- 995 135. Hakeem R, Sheikh MA. Beyond transmission: Dire need for integration of nutrition
996 interventions in COVID-19 pandemic-response strategies in Developing Countries like Pakistan.
997 *Pak J Med Sci*. 2020;36(Covid19-s4):S85-s9. doi: 10.12669/pjms.36.COVID19-S4.2784.
998 PubMed PMID: 32582320.
- 999 136. Sidor A, Rzymiski P. Dietary Choices and Habits during COVID-19 Lockdown:
1000 Experience from Poland. *Nutrients*. 2020;12(6). doi: 10.3390/nu12061657. PubMed PMID:
1001 32503173.
- 1002 137. Bhatia V, Mandal P, Satyanarayana S, Aditama T, Sharma M. Mitigating the impact of
1003 the COVID-19 pandemic on progress towards ending tuberculosis in the WHO South-East Asia
1004 Region. *WHO South-East Asia Journal of Public Health*. 2020;9(2):95-9. doi: 10.4103/2224-
1005 3151.294300.
- 1006 138. Dieppe A, Kose MA. The Global Productivity Slump: What Policies to Rekindle?
1007 ([https://www.brookings.edu/research/the-global-productivity-slump-what-policies-to-](https://www.brookings.edu/research/the-global-productivity-slump-what-policies-to-rekindle/#footnote-2)
1008 [rekindle/#footnote-2](https://www.brookings.edu/research/the-global-productivity-slump-what-policies-to-rekindle/#footnote-2)). Washington DC: 2020.
- 1009 139. Naidoo R, Fisher B. Reset Sustainable Development Goals for a pandemic world. *Nature*.
1010 2020;583(7815):198-201. Epub 2020/07/08. doi: 10.1038/d41586-020-01999-x. PubMed PMID:
1011 32632244.
- 1012 140. Hall KS, Samari G, Garbers S, Casey SE, Diallo DD, Orcutt M, et al. Centring sexual and
1013 reproductive health and justice in the global COVID-19 response. *Lancet*.
1014 2020;395(10231):1175-7. PubMed PMID: 32278371.
- 1015 141. UNFPA, Avenir Health, Johns Hopkins University, Victoria University. Impact of the
1016 COVID-19 Pandemic on Family Planning and Ending Gender-based Violence, Female Genital
1017 Mutilation and Child Marriage. Pandemic threatens achievement of the Transformative Results
1018 committed to by UNFPA. [https://www.unfpa.org/sites/default/files/resource-pdf/COVID-](https://www.unfpa.org/sites/default/files/resource-pdf/COVID-19_impact_brief_for_UNFPA_24_April_2020_1.pdf)
1019 [19_impact_brief_for_UNFPA_24_April_2020_1.pdf](https://www.unfpa.org/sites/default/files/resource-pdf/COVID-19_impact_brief_for_UNFPA_24_April_2020_1.pdf); UNFPA, April, 2020.
- 1020 142. Kumar N. COVID 19 era: a beginning of upsurge in unwanted pregnancies, unmet need
1021 for contraception and other women related issues. *Eur J Contracept Reprod Health Care*.
1022 2020;25(4):323-5. doi: 10.1080/13625187.2020.1777398. PubMed PMID: 32567961.
- 1023 143. Bekker LG, Alleyne G, Baral S, Cepeda J, Daskalakis D, Dowdy D, et al. Advancing
1024 global health and strengthening the HIV response in the era of the Sustainable Development
1025 Goals: the International AIDS Society-Lancet Commission. *Lancet*. 2018;392(10144):312-58.
1026 Epub 2018/07/24. doi: 10.1016/s0140-6736(18)31070-5. PubMed PMID: 30032975; PubMed
1027 Central PMCID: PMC6323648.
- 1028 144. Zuckerman G, McKay B. How HIV Research Laid the Foundation for COVID Vaccines.
1029 *Wall Street Journal*. 2020.
- 1030 145. amfAR. The Broad Benefits of AIDS Research. New York, NY: 2020.
- 1031 146. WHO. TB and HIV, and other comorbidities 2020. Available from:
1032 <https://www.who.int/tb/areas-of-work/tb->

- 1033 hiv/en/#:~:text=TB%20is%20the%20most%20common,HIV%2Dassociated%20TB%20in%20
1034 018.
- 1035 147. Bonn M, Palayew A, Bartlett S, Brothers TD, Touesnard N, Tyndall M. Addressing the
1036 Syndemic of HIV, Hepatitis C, Overdose, and COVID-19 Among People Who Use Drugs: The
1037 Potential Roles for Decriminalization and Safe Supply. *Journal of studies on alcohol and drugs*.
1038 2020;81(5):556-60. Epub 2020/10/09. PubMed PMID: 33028465.
- 1039 148. Pérez-Escamilla R, Cunningham K, Moran VH. COVID-19 and maternal and child food
1040 and nutrition insecurity: a complex syndemic. *Maternal & child nutrition*. 2020;16(3):e13036.
1041 Epub 2020/05/28. doi: 10.1111/mcn.13036. PubMed PMID: 32458574; PubMed Central
1042 PMCID: PMC7267083.
- 1043 149. Poteat T, Millett GA, Nelson LE, Beyrer C. Understanding COVID-19 risks and
1044 vulnerabilities among black communities in America: the lethal force of syndemics. *Annals of
1045 epidemiology*. 2020;47:1-3. Epub 2020/05/19. doi: 10.1016/j.annepidem.2020.05.004. PubMed
1046 PMID: 32419765; PubMed Central PMCID: PMC7224650.
- 1047 150. Venkatesh V. Impacts of COVID-19: A research agenda to support people in their fight.
1048 *International journal of information management*. 2020;55:102197. Epub 2020/08/25. doi:
1049 10.1016/j.ijinfomgt.2020.102197. PubMed PMID: 32836648; PubMed Central PMCID:
1050 PMC7368151.
- 1051 151. Queiroz MM, Ivanov D, Dolgui A, Fosso Wamba S. Impacts of epidemic outbreaks on
1052 supply chains: mapping a research agenda amid the COVID-19 pandemic through a structured
1053 literature review. *Annals of operations research*. 2020:1-38. Epub 2020/08/25. doi:
1054 10.1007/s10479-020-03685-7. PubMed PMID: 32836615; PubMed Central PMCID:
1055 PMC7298926.
- 1056 152. Oyebo O, Ramsay SE, Brayne C. Public health research in the UK to understand and
1057 mitigate the impact of COVID-19 and COVID-19 response measures. *Journal of epidemiology
1058 and community health*. 2020. Epub 2020/10/09. doi: 10.1136/jech-2020-214997. PubMed PMID:
1059 33028615.
- 1060 153. Shiau S, Krause KD, Valera P, Swaminathan S, Halkitis PN. The Burden of COVID-19
1061 in People Living with HIV: A Syndemic Perspective. *AIDS Behav*. 2020;24(8):2244-9. Epub
1062 2020/04/19. doi: 10.1007/s10461-020-02871-9. PubMed PMID: 32303925; PubMed Central
1063 PMCID: PMC7165075.
- 1064 154. Yadav UN, Rayamajhee B, Mistry SK, Parsekar SS, Mishra SK. A Syndemic Perspective
1065 on the Management of Non-communicable Diseases Amid the COVID-19 Pandemic in Low-
1066 and Middle-Income Countries. *Frontiers in public health*. 2020;8:508. Epub 2020/10/27. doi:
1067 10.3389/fpubh.2020.00508. PubMed PMID: 33102414; PubMed Central PMCID:
1068 PMC7545493.
- 1069 155. Hollingsworth TD. Controlling infectious disease outbreaks: Lessons from mathematical
1070 modelling. *J Public Health Policy*. 2009;30(3):328-41. Epub 2009/10/07. doi:
1071 10.1057/jphp.2009.13. PubMed PMID: 19806073; PubMed Central PMCID:
1072 PMC7099230.
- 1073 156. Viboud C, Sun K, Gaffey R, Ajelli M, Fumanelli L, Merler S, et al. The RAPIDD ebola
1074 forecasting challenge: Synthesis and lessons learnt. *Epidemics*. 2018;22:13-21. Epub
1075 2017/09/30. doi: 10.1016/j.epidem.2017.08.002. PubMed PMID: 28958414; PubMed Central
1076 PMCID: PMC5927600.
- 1077 157. Thompson RN, Hollingsworth TD, Isham V, Arribas-Bel D, Ashby B, Britton T, et al.
1078 Key questions for modelling COVID-19 exit strategies. *Proc Biol Sci*.

1079 2020;287(1932):20201405. Epub 2020/08/13. doi: 10.1098/rspb.2020.1405. PubMed PMID:
1080 32781946; PubMed Central PMCID: PMC7575516.
1081 158. Development. OfECa. Health Care Resources: Hospital Beds
1082 (<https://stats.oecd.org/index.aspx?queryid=30183>). 2020.
1083 159. Scheffler R. The Labour market for human resources for health in low- and middle-
1084 income countries (https://www.who.int/hrh/resources/Observer11_WEB.pdf). Geneva: 2012.
1085 160. WHO. Global Health Observatory data repository
1086 (<https://apps.who.int/gho/data/node.main.MHHR?lang=en>). Geneva: 2019.
1087 161. Carias C, Pawaskar M, Nyaku M, Conway JH, Roberts CS, Finelli L, et al. Potential
1088 impact of COVID-19 pandemic on vaccination coverage in children: A case study of measles-
1089 containing vaccine administration in the United States (US). *Vaccine*. 2020. Epub 2020/12/19.
1090 doi: 10.1016/j.vaccine.2020.11.074. PubMed PMID: 33334618; PubMed Central PMCID:
1091 PMC7723783.
1092 162. Hartnett KP, Kite-Powell A, DeVies J, Coletta MA, Boehmer TK, Adjemian J, et al.
1093 Impact of the COVID-19 Pandemic on Emergency Department Visits - United States, January 1,
1094 2019-May 30, 2020. *MMWR Morb Mortal Wkly Rep*. 2020;69(23):699-704. Epub 2020/06/12.
1095 doi: 10.15585/mmwr.mm6923e1. PubMed PMID: 32525856; PubMed Central PMCID:
1096 PMC7315789 Journal Editors form for disclosure of potential conflicts of interest. No
1097 potential conflicts of interest were disclosed.
1098 163. Dyer O. Covid-19: Pandemic is having "severe" impact on non-communicable disease
1099 care, WHO survey finds. *BMJ*. 2020;369:m2210. Epub 2020/06/05. doi: 10.1136/bmj.m2210.
1100 PubMed PMID: 32493728.
1101 164. Strully K, Yang TC, Liu H. Regional variation in COVID-19 disparities: connections
1102 with immigrant and Latinx communities in U.S. counties. *Ann Epidemiol*. 2021;53:56-62 e2.
1103 Epub 2020/09/15. doi: 10.1016/j.annepidem.2020.08.016. PubMed PMID: 32927056; PubMed
1104 Central PMCID: PMC7485497.
1105 165. Noman AHM, Griffiths MD, Pervin S, Ismail MN. The detrimental effects of the
1106 COVID-19 pandemic on domestic violence against women. *J Psychiatr Res*. 2020;134:111-2.
1107 Epub 2021/01/01. doi: 10.1016/j.jpsychires.2020.12.057. PubMed PMID: 33383493.
1108 166. Wang Y, Kala MP, Jafar TH. Factors associated with psychological distress during the
1109 coronavirus disease 2019 (COVID-19) pandemic on the predominantly general population: A
1110 systematic review and meta-analysis. *PLoS One*. 2020;15(12):e0244630. Epub 2020/12/29. doi:
1111 10.1371/journal.pone.0244630. PubMed PMID: 33370404.
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124

1125

1126 **APPENDIX: Search Strategies**

1127

1128 **HIV**

1129 (((("COVID-19"[tw] OR "COVID 19"[tw] OR "COVID19"[tw] OR "COVID2019"[tw] OR
1130 "COVID 2019"[tw] OR "COVID-2019"[tw] OR "novel coronavirus"[tw] OR "new
1131 coronavirus"[tw] OR "novel corona virus"[tw] OR "new corona virus"[tw] OR "SARS-CoV-
1132 2"[tw] OR "SARSCoV2"[tw] OR "SARS-CoV2"[tw] OR "2019nCoV"[tw] OR "2019-
1133 nCoV"[tw] OR "2019 coronavirus"[tw] OR "2019 corona virus"[tw] OR "coronavirus disease
1134 2019"[tw] OR "severe acute respiratory syndrome coronavirus 2"[nm] OR "severe acute
1135 respiratory syndrome coronavirus 2"[tw] OR "sars-coronavirus-2"[tw] OR "coronavirus disease
1136 2019"[tw] OR "corona virus disease 2019"[tw])) AND (("2020/MM/DD"[PDAT] :
1137 "3000/MM/DD"[PDAT]))) AND ("HIV"[Mesh] OR "Acquired Immunodeficiency
1138 Syndrome"[Mesh] OR "HIV Infections"[Mesh] OR human immunodeficiency virus*[tw] OR
1139 acquired immunodeficiency syndrome*[tw] OR HIV*[tw] OR "AIDS"[tw] OR HIV1*[tw] OR
1140 HIV2*[tw])

1141

1142 **Malnutrition**

1143 (((("COVID-19"[tw] OR "COVID 19"[tw] OR "COVID19"[tw] OR "COVID2019"[tw] OR
1144 "COVID 2019"[tw] OR "COVID-2019"[tw] OR "novel coronavirus"[tw] OR "new
1145 coronavirus"[tw] OR "novel corona virus"[tw] OR "new corona virus"[tw] OR "SARS-CoV-
1146 2"[tw] OR "SARSCoV2"[tw] OR "SARS-CoV2"[tw] OR "2019nCoV"[tw] OR "2019-
1147 nCoV"[tw] OR "2019 coronavirus"[tw] OR "2019 corona virus"[tw] OR "coronavirus disease
1148 2019"[tw] OR "severe acute respiratory syndrome coronavirus 2"[nm] OR "severe acute
1149 respiratory syndrome coronavirus 2"[tw] OR "sars-coronavirus-2"[tw] OR "coronavirus disease
1150 2019"[tw] OR "corona virus disease 2019"[tw])) AND (("2020/MM/DD"[PDAT] :
1151 "3000/MM/DD"[PDAT]))) AND ("Infant nutrition disorders"[Mesh] OR "child nutrition
1152 disorders"[Mesh] OR "malnutrition"[Mesh] OR "thinness"[Mesh] OR "wasting syndrome"
1153 [Mesh] OR "undernutrition"[tw] OR undernourish*[tw] OR "chronic energy deficiency"[tw] OR
1154 "stunting"[tw] OR "wasting"[tw] OR "underweight"[tw] OR "thinness"[tw] OR micronutrient
1155 deficienc*[tw] OR vitamin deficienc*[tw] OR mineral deficienc*[tw])

1156

1157 **Malaria**

1158 (((("COVID-19"[tw] OR "COVID 19"[tw] OR "COVID19"[tw] OR "COVID2019"[tw] OR
1159 "COVID 2019"[tw] OR "COVID-2019"[tw] OR "novel coronavirus"[tw] OR "new
1160 coronavirus"[tw] OR "novel corona virus"[tw] OR "new corona virus"[tw] OR "SARS-CoV-
1161 2"[tw] OR "SARSCoV2"[tw] OR "SARS-CoV2"[tw] OR "2019nCoV"[tw] OR "2019-
1162 nCoV"[tw] OR "2019 coronavirus"[tw] OR "2019 corona virus"[tw] OR "coronavirus disease
1163 2019"[tw] OR "severe acute respiratory syndrome coronavirus 2"[nm] OR "severe acute
1164 respiratory syndrome coronavirus 2"[tw] OR "sars-coronavirus-2"[tw] OR "coronavirus disease
1165 2019"[tw] OR "corona virus disease 2019"[tw])) AND (("2020/MM/DD"[PDAT] :
1166 "3000/MM/DD"[PDAT]))) AND ("Malaria" [Mesh] OR "malaria" [tw] OR "plasmodium" [tw])

1167

1168 **TB**

1169 (((("COVID-19"[tw] OR "COVID 19"[tw] OR "COVID19"[tw] OR "COVID2019"[tw] OR
1170 "COVID 2019"[tw] OR "COVID-2019"[tw] OR "novel coronavirus"[tw] OR "new

1171 coronavirus"[tw] OR "novel corona virus"[tw] OR "new corona virus"[tw] OR "SARS-CoV-
1172 2"[tw] OR "SARSCoV2"[tw] OR "SARS-CoV2"[tw] OR "2019nCoV"[tw] OR "2019-
1173 nCoV"[tw] OR "2019 coronavirus"[tw] OR "2019 corona virus"[tw] OR "coronavirus disease
1174 2019"[tw] OR "severe acute respiratory syndrome coronavirus 2"[nm] OR "severe acute
1175 respiratory syndrome coronavirus 2"[tw] OR "sars-coronavirus-2"[tw] OR "coronavirus disease
1176 2019"[tw] OR "corona virus disease 2019"[tw])) AND (("2020/MM/DD"[PDAT] :
1177 "3000/MM/DD"[PDAT])) AND ("Tuberculosis" [Mesh] OR "tuberculosis" [tw] OR "TB"[tw]
1178 OR mycobacter*[tw])
1179

1180 Sexual and Reproductive Health

1181 (((("COVID-19"[tw] OR "COVID 19"[tw] OR "COVID19"[tw] OR "COVID2019"[tw] OR
1182 "COVID 2019"[tw] OR "COVID-2019"[tw] OR "novel coronavirus"[tw] OR "new
1183 coronavirus"[tw] OR "novel corona virus"[tw] OR "new corona virus"[tw] OR "SARS-CoV-
1184 2"[tw] OR "SARSCoV2"[tw] OR "SARS-CoV2"[tw] OR "2019nCoV"[tw] OR "2019-
1185 nCoV"[tw] OR "2019 coronavirus"[tw] OR "2019 corona virus"[tw] OR "coronavirus disease
1186 2019"[tw] OR "severe acute respiratory syndrome coronavirus 2"[nm] OR "severe acute
1187 respiratory syndrome coronavirus 2"[tw] OR "sars-coronavirus-2"[tw] OR "coronavirus disease
1188 2019"[tw] OR "corona virus disease 2019"[tw])) AND (("2020/MM/DD"[PDAT] :
1189 "3000/MM/DD"[PDAT])) AND ("Reproductive Health" [Mesh] OR "Reproductive Health
1190 Services"[Mesh] OR "maternal health"[Mesh] OR "maternal health services"[Mesh] OR
1191 "reproductive health"[tw] OR "maternal health"[tw] OR "contracept*[tw] OR "family planning"[tw]
1192 OR "abortion"[tw] OR "post-abortion care"[tw] OR "unintended pregnancy"[tw] OR "unplanned
1193 pregnancy"[tw] OR "unwanted pregnancy"[tw])
1194
1195
1196
1197
1198